By: Carlos Arce

Introduction

In a major enforcement action that has shaken the digital health sector, a federal grand jury in San Francisco returned an indictment on December 17, 2025 charging a California telehealth provider and a Florida medical practice with orchestrating a sophisticated and lucrative scheme to distribute Adderall and other stimulant medications over the internet, allegedly generating over $100 million in unlawful revenue.

The indictment represents one of the most significant criminal actions taken against a telemedicine platform to date, underscoring growing concerns among regulators about the misuse of digital health models to circumvent well-established medical, legal, and regulatory safeguards.

The Alleged Scheme: How It Worked

At the center of the indictment is Done Global Inc., a California-based digital health company that marketed itself as an online provider of diagnosis, treatment, and medication refills for Attention Deficit Hyperactivity Disorder (ADHD). Patients could reportedly sign up for a subscription-based model, paying a monthly fee for continued access to clinicians and prescriptions. Prosecutors allege that the business model was designed less for legitimate care and more to maximize prescription volume, and corporate profits.

According to the indictment:

• Done Global and a Florida medical practice identified as Mindful Mental Wellness P.A. (MMW) conspired to provide patients with prescriptions for Adderall and other stimulants that were not issued for legitimate medical purposes.
• Together, they allegedly arranged for more than 40 million pills to be prescribed and obtained, a volume that prosecutors say far outstripped genuine medical need.
• These prescriptions were filled through pharmacies and reimbursed by Medicare, Medicaid, and commercial insurers, often without proper examinations or established patient-provider relationships.

Prosecutors also allege that the companies defrauded pharmacies and insurers, and even conspired to alter, destroy, or conceal records after receiving a grand jury subpoena. The key thing to take here is the justice system is tracking down on medical necessity, a key element which must be at the center of any telehealth platform when promoting and later prescribing to the general public.

Criminal Charges and Potential Penalties

The indictment brings multiple serious charges:

• Conspiracy to illegally distribute controlled substances, including Adderall.
• Four counts of illegal distribution of Adderall.
• Conspiracy to commit health care fraud in connection with false and fraudulent claims.
• Conspiracy to obstruct justice.

If convicted, the corporate entities face penalties that could include financial sanctions up to twice the gross profits or loss tied to the offenses, a significant deterrent in cases of large-scale fraud.

Regulatory and Public Health Implications

Federal officials have pushed back strongly against the alleged misconduct. Statements from the Department of Justice, the Drug Enforcement Administration (DEA), and the Department of Health and Human Services Office of Inspector General (HHS-OIG) emphasized that exploiting telemedicine to dispense controlled substances without proper medical oversight not only defrauds public and private payors but also risks public health by making addictive stimulants improperly accessible.

This case highlights the tension between the promise of telehealth, expanding access, convenience, and efficiency; and the need for rigorous compliance, ethical prescribing, and patient safety protocols. As digital health platforms proliferate, authorities have signaled they will continue to enforce the same standards that apply to traditional medical practices.

A Broader Warning: This Risk Extends to the Entire Telehealth Ecosystem

Perhaps the most important takeaway from this case is that the risk is not isolated.

Federal enforcement agencies are making it clear that all telehealth platforms are exposed particularly those that:

• Advertise or promote specific drugs, especially controlled substances
• Operate high-volume or subscription-based prescribing models
• Rely heavily on digital marketing funnels to drive patient acquisition
• Partner with affiliated or third-party pharmacies for fulfillment

Importantly, regulatory risk does not turn on payment structure. Whether a platform is cash-pay, insurance-based, or hybrid, the same fraud, abuse, and controlled-substance laws apply. Prosecutors have shown they are willing to pursue cases involving:

• Telehealth companies
• Medical practices and supervising clinicians
• Marketing companies generating patient leads tied to prescriptions
• Drop-ship or fulfillment pharmacies that fill and distribute medications

In other words, liability can attach across the entire supply chain.

Marketing, Prescribing, and Pharmacy Fulfillment Are Now Linked Risks

One of the most significant implications of this case is the DOJ’s apparent willingness to connect advertising, prescribing behavior, and drug distribution into a single enforcement theory.

Telehealth platforms and their partners must now assume that:

• Drug-specific marketing may be viewed as evidence of intent
• High-conversion advertising tied to scheduled drugs increases scrutiny
• Pharmacy relationships can expose platforms to downstream liability
• “Technology company” defenses will not shield clinical decision-making

This is especially relevant for platforms that blur the lines between care delivery, marketing, and fulfillment under a single brand experience.

The Compliance Message Is Clear

Federal regulators have sent an unmistakable message: Virtual care does not excuse virtual compliance.

Telehealth companies, marketing firms, and pharmacy partners must proactively evaluate:

• Controlled-substance prescribing protocols
• Marketing language and ad targeting strategies
• Provider independence and medical necessity standards
• Pharmacy relationships and fulfillment controls
• Documentation, audit trails, and data retention practices

Failure to do so may expose all parties, not just prescribers, to criminal, civil, and administrative liability.

Conclusion

This indictment represents more than a single prosecution; it signals a broader enforcement roadmap for the telehealth industry. With federal authorities now testing clear precedent, telemedicine companies can expect increased scrutiny of how controlled substances are prescribed, how clinical oversight is structured, and whether revenue models incentivize compliance or volume. While the case itself remains ongoing, the message from enforcement agencies is unmistakable: virtual care is not a regulatory safe harbor. For digital health platforms operating anywhere near controlled substances, the takeaway is urgent and unavoidable, telehealth innovation must be built on compliance, not conversion.